The results showed that variations within SLC1A1 (EAAT3) and SLC1A3 (EAAT1) increase the risk of epilepsy after sTBI, which may serve as potential drug targets for PTS.120, 121. The gene discussed is SLC1A1; the disease is epilepsy.